Início › Leucemia Bifenotípica Aguda › Nova York

Ensaios clínicos de Leucemia Bifenotípica Aguda em Nova York

11 estudos para Leucemia Bifenotípica Aguda estão buscando participantes em locais em Nova York.

Cidades em Nova York

Texto oficial do estudo (Inglês)

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 1

Idades de 12 a 78 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
e mais 7

RecrutandoFase 2

365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Montefiore Medical Center, New York

RecrutandoFase 1/2

30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
e mais 12

RecrutandoFase 3

365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
e mais 7

RecrutandoFase 1/2

Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

RecrutandoFase 1/2

Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Memorial Sloan- Kettering Cancer Center, New York

RecrutandoFase 1

Idades de 1 a 30 · Todos os sexos · Atualizado em 3 de ago. de 2026 · NCT06177067

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Weill Cornell Medicine - New York Presbyterian Hospital, New York

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT07216443

A Study of Revumenib and Mezigdomide in People With Leukemia

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
e mais 1

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT07356154

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 1

Idades 12 e acima · Todos os sexos · Atualizado em 8 de jan. de 2026 · NCT04872478

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Children's Hospital New York-Presbyterian, New York
Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 1

Idades de 1 a 21 · Todos os sexos · Atualizado em 6 de dez. de 2024 · NCT05476770

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.